导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.51% | 1242/3266 |
| 近一周 | -1.52% | 1540/3690 |
| 近一月 | -3.22% | 1528/3663 |
| 近一季 | -6.18% | 1600/3534 |
| 近半年 | -1.15% | 1189/3357 |
| 近一年 | 6.32% | 1103/3056 |
| 近两年 | 60.39% | 871/2167 |
| 近三年 | 39.27% | 549/1638 |
| 成立以来 | 65.65% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.52% 2342/4961 |
14.60% 1789/5312 |
- - |
- - |
| 2025 | 24.57% 1784/4813 |
0.37% 1880/3635 |
2.49% 1541/4076 |
19.90% 2082/4524 |
1.00% 1608/4813 |
| 2024 | 15.73% 891/3463 |
1.68% 864/2808 |
-2.13% 1141/3014 |
16.91% 1316/3129 |
-0.52% 1452/3463 |
| 2023 | -6.96% 885/2656 |
5.31% 803/2280 |
-3.93% 974/2385 |
-2.76% 743/2515 |
-5.43% 1352/2655 |
| 2022 | -19.87% 910/2207 |
-13.63% 801/1919 |
5.55% 877/2016 |
-12.73% 771/2113 |
0.71% 1464/2208 |
| 2021 | 1.34% 680/1822 |
-3.03% 743/1255 |
6.01% 773/1330 |
-3.25% 624/1466 |
1.89% 760/1822 |
| 2020 | 40.15% 315/1250 |
-6.24% 473/1028 |
16.60% 429/1067 |
14.35% 282/1164 |
12.12% 500/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 易方达中证800ETF联接C VS. 长安沪深300非周期A(740101) |